WO2008045576A3 - Compositions and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases - Google Patents

Compositions and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases Download PDF

Info

Publication number
WO2008045576A3
WO2008045576A3 PCT/US2007/021985 US2007021985W WO2008045576A3 WO 2008045576 A3 WO2008045576 A3 WO 2008045576A3 US 2007021985 W US2007021985 W US 2007021985W WO 2008045576 A3 WO2008045576 A3 WO 2008045576A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
cancer
treatment
rnai therapeutics
Prior art date
Application number
PCT/US2007/021985
Other languages
French (fr)
Other versions
WO2008045576A2 (en
Inventor
Yijia Liu
Patrick Y Lu
Martin C Woodle
Frank Y Xie
Xiao Dong Yang
Quinn Tang
Original Assignee
Yijia Liu
Patrick Y Lu
Martin C Woodle
Frank Y Xie
Xiao Dong Yang
Quinn Tang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yijia Liu, Patrick Y Lu, Martin C Woodle, Frank Y Xie, Xiao Dong Yang, Quinn Tang filed Critical Yijia Liu
Publication of WO2008045576A2 publication Critical patent/WO2008045576A2/en
Publication of WO2008045576A3 publication Critical patent/WO2008045576A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Abstract

The invention relates to oligonucleotide compositions for use in reducing the expression and activity of VEGF pathway genes and unwanted neovascularization, including tumor angiogenesis, by RNA interference and methods and compositions comprising the oligonucleotides.
PCT/US2007/021985 2006-10-12 2007-10-12 Compositions and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases WO2008045576A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US85164706P 2006-10-12 2006-10-12
US60/851,647 2006-10-12
US85327406P 2006-10-19 2006-10-19
US60/853,274 2006-10-19
US92774407P 2007-05-04 2007-05-04
US60/927,744 2007-05-04

Publications (2)

Publication Number Publication Date
WO2008045576A2 WO2008045576A2 (en) 2008-04-17
WO2008045576A3 true WO2008045576A3 (en) 2009-02-26

Family

ID=39283488

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/021985 WO2008045576A2 (en) 2006-10-12 2007-10-12 Compositions and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases

Country Status (1)

Country Link
WO (1) WO2008045576A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2604441A1 (en) 2005-04-12 2006-10-19 Intradigm Corporation Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
SI2056845T1 (en) 2006-08-08 2018-02-28 Rheinische Friedrich-Wilhelms-Universitaet Bonn Structure and use of 5' phosphate oligonucleotides
US20100210710A1 (en) * 2007-10-12 2010-08-19 Intradigm Corporation THERAPEUTIC siRNA MOLECULES FOR REDUCING VEGFR1 EXPRESSION IN VITRO AND IN VIVO
US9738680B2 (en) 2008-05-21 2017-08-22 Rheinische Friedrich-Wilhelms-Universität Bonn 5′ triphosphate oligonucleotide with blunt end and uses thereof
SG10201510586PA (en) 2008-06-30 2016-01-28 Mesoblast Inc Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy
JP2013539456A (en) * 2010-07-28 2013-10-24 アルコン リサーチ，リミテッド SiRNA Targeting VEGFA and Methods for In Vivo Treatment
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
CN107177598B (en) * 2016-08-18 2019-12-27 广州市锐博生物科技有限公司 Oligonucleotide molecule for inhibiting mRNA expression of BIRC5 target gene and its composition set
EP3762497A4 (en) * 2018-05-14 2022-08-03 Murdoch University Methods for treating vegf-related conditions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009769A2 (en) * 2002-07-24 2004-01-29 The Trustees Of The University Of Pennsylvania COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS
WO2005076998A2 (en) * 2004-02-05 2005-08-25 Intradigm Corporation Rnai therapeutics for treatment of eye neovascularization diseases
WO2006110813A2 (en) * 2005-04-12 2006-10-19 Intradigm Corporation Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
WO2007146953A2 (en) * 2006-06-12 2007-12-21 Exegenics, Inc., D/B/A Opko Health, Inc. Compositions and methods for sirna inhibition of angiogenesis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009769A2 (en) * 2002-07-24 2004-01-29 The Trustees Of The University Of Pennsylvania COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS
WO2005076998A2 (en) * 2004-02-05 2005-08-25 Intradigm Corporation Rnai therapeutics for treatment of eye neovascularization diseases
WO2006110813A2 (en) * 2005-04-12 2006-10-19 Intradigm Corporation Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
WO2007146953A2 (en) * 2006-06-12 2007-12-21 Exegenics, Inc., D/B/A Opko Health, Inc. Compositions and methods for sirna inhibition of angiogenesis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TOLENTINO M J ET AL: "INTRAVITREAL INJECTION OF VASCULAR ENDOTHELIAL GROWTH FACTOR SMALL INTERFERING RNA INHIBITS GROWTH AND LEAKAGE IN A NONHUMAN PRIMATE, LASER-INDUCED MODEL OF CHOROIDAL NEOVASCULARIZATION", RETINA, PHILADELPHIA, PA, US, no. 1, 1 February 2004 (2004-02-01), pages 132 - 138, XP009063917, ISSN: 0275-004X *

Also Published As

Publication number Publication date
WO2008045576A2 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
WO2008045576A3 (en) Compositions and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
WO2010065787A3 (en) Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
WO2008137867A3 (en) Compositions comprising mir34 therapeutic agents for treating cancer
WO2014022739A3 (en) Modified rnai agents
MX2018012038A (en) Modified rnai agents.
IL215682A0 (en) Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
SG161267A1 (en) Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
WO2012075040A3 (en) mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
WO2009142822A3 (en) 2-f modified rna interference agents
WO2007095316A3 (en) Compositions and methods for oligonucleotide formulations
WO2004009769A3 (en) COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS
WO2009105260A3 (en) Ultra-small rnas as toll-like receptor-3 antagonists
WO2004094606A3 (en) COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOPOIETIN 1 AND 2 AND THEIR RECEPTOR TIE2
WO2011085066A3 (en) Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
MX2009006310A (en) Compositions and methods to treat muscular & cardiovascular disorders.
WO2009045356A8 (en) Microrna compositions in the treatment of vegf-mediated disorders
WO2010151674A3 (en) Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
WO2009017803A3 (en) Antisense microrna and uses therefor
WO2010017436A3 (en) Modulation of myeloid differentation primary response gene 88 (myd88) expression by antisense oligonucleotides
WO2009095517A3 (en) Methods and compositions capable of causing post-transcriptional silencing of gene expression in a synergic manner
WO2010017152A3 (en) Modulation of toll-like receptor 8 expression by antisense oligonucleotides
WO2008086182A3 (en) Use of gene signatures to design novel cancer treatment regimens
WO2009051659A3 (en) Therapeutic sirna molecules for reducing vegfr1 expression in vitro and in vivo
WO2012009703A3 (en) Targeted nanoparticles for cancer and other disorders
WO2010017154A3 (en) Modulation of toll-like receptor 3 expression by antisense oligonucleotides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07867232

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07867232

Country of ref document: EP

Kind code of ref document: A2